Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Imfinzi Faces Price Slash of 25%, Polivy 15% in February: Quarterly Re-Pricing
AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab) and Chugai Pharmaceutical’s antibody drug conjugate (ADC) Polivy (polatuzumab vedotin) were caught by the quarterly re-pricing scheme for their rosy revenues. Their prices will be pared by 25% and 15%, respectively, effective February 1. The…
To read the full story
Related Article
REGULATORY
- Yaz, Actemra Indications Deemed High-Need by MHLW Panel
September 7, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
- UK Halts Tavneos for New Patients, Approval Revocation Set for March
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…